Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Everest Launches Novel Antibiotic in China for Difficult/Drug Resistant Infections

publication date: Jul 27, 2023

Shanghai Everest Medicines launched its first product, Xerava® (eravacycline), a novel antibiotic, in China. Xerava is the world's first fluorocycline antibiotic for infections caused by susceptible gram positive, gram negative and anaerobic pathogens including multidrug resistant infections. In 2018, Everest in-licensed the antibiotic from Tetraphase in a $35 million agreement. Clinical trials of the product showed it provided broad bacterial spectrum coverage and high potency against multidrug-resistant bacterial infections. An in-licensing company, Everest is now a commercial-stage biopharma. More details....

Stock Symbol: (HK: 1952)

Share this with colleagues: